Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.66 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.66 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.66 |
| ▸ | CDK1 | P06493 | 9/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.65 |
| ▸ | MGMT | P16455 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATR | Q13535 | 1/20 | 0.57 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16828242 | 0.91 | CCNA2 (0.53) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL18134206 | 0.84 | CCNA2 (0.48) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL2056438 | 0.83 | CCNA2 (0.67) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL16464209 | 0.81 | CDK2 (0.73) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL16464872 | 0.81 | CDK2 (0.63) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL16464949 | 0.79 | CDK2 (1.00) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL16463323 | 0.79 | CDK2 (0.66) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL16465651 | 0.79 | CDK2 (1.00) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL16463170 | 0.78 | CDK2 (0.63) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL2054835 | 0.76 | MGMT (1.00) | CDK2CCNA2CCNA1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-12-21 | — | — | US | disclosed |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-08-24 | — | — | US | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1658081-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005021003-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | CDK2 636/4885CCNA2 1165/4885CCNA1 722/4885 |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | CDK2 663/4885CCNA2 1188/4885CCNA1 782/4885 |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | CDK2 636/4885CCNA2 1165/4885CCNA1 722/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | CDK2 2395/4885CCNA2 2278/4885CCNA1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.